Oncology
Novartis bags paediatric FDA label expansion for Lutathera
Novartis has received a US Food and Drug Administration (FDA) approval for the label expansion of its peptide receptor radionuclide…
ImmunityBio’s ANKTIVA receives FDA approval for bladder cancer
The US Food and Drug Administration (FDA) has granted approval for ImmunityBio's ANKTIVA, plus Bacillus Calmette-Guérin (BCG), for treating patients…
Health Canada approves Merck’s Keytruda for gastric cancer treatment
Health Canada has approved Merck & Co Inc (MSD)’s Keytruda (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for…
Roche wins second FDA label expansion for Alecensa in NSCLC
The US Food and Drug Administration (FDA) has granted a label expansion to Roche’s Alecensa (alectinib) as an adjuvant therapy…
OncoX inks licensing deal worth over $26m for NSCLC therapy
US-based ABVC BioPharma has sold the rights to its botanical drug extract therapy, BLEX 404, for the treatment of non-small…
Theolytics secures funds to advance oncolytic adenovirus therapy
UK-based biotechnology company Theolytics has concluded a funding round securing a total of £19m ($24.5m) to advance the development of…
Ultimovacs downsizes to funnel funds to cancer vaccine programme
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…
Portage mulls company closure, pauses enrolment for lead clinical programme
US-based Portage Biotech is cash-strapped and has started looking for strategic alternatives including a wind-down of the company. The company…
Sanofi advances NK cell engager to Phase II for blood cancer treatment
Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use…
Candel wins FDA orphan drug designation for pancreatic cancer drug
The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for…
